Overview
GLOW usually refers to BPC-157, TB-500, and GHK-Cu.[1] The research cited here does not establish clinical benefit from that three-peptide blend. GHK-Cu skin findings concern a topical regimen; the BPC-157/TB-500 experiment tested a different, two-ingredient intervention.[2][3] The evidence therefore needs to be read at the level of the actual intervention and measured outcome. This guide separates findings about the individual ingredients from findings about the complete combination, and keeps unresolved questions about formulation, benefit, and safety visible.
Ingredients
- BPC-157Read the injury-recovery and safety evidence.
- TB-500Check the distinction between thymosin beta-4 and its fragments.
- GHK-CuKeep topical and injectable research separate.
“Contains GHK-Cu” is not a complete research match. A topical skin product, an injected peptide, and a three-component blend need separate assessments. Read the GHK-Cu guide for the evidence tied to each route. Ingredient names identify the proposed combination, but interpreting a study also requires the chemical identity and preparation actually tested. A paper about one ingredient, a different fragment, or a different route does not automatically apply to the complete blend described on this page.
Why combine them?
The rationale links two separate research topics: BPC-157 with TB-500 in tendon healing, and topical GHK-Cu in skin care. These studies provide questions to investigate; neither tests whether combining all three improves a clinical outcome.[2][3] A proposed reason to combine ingredients is a research question rather than a demonstrated advantage. To support an added benefit, a study needs to compare the complete combination with relevant alternatives and measure outcomes that matter to the intended use.
Combination benefits
A randomized study of skin care after CO2 laser resurfacing had 13 completers. A GHK-Cu regimen improved a subjective skin-quality rating, but objective wrinkle, skin-quality, and redness comparisons did not differ significantly between groups.[2] That result cannot establish that injected GLOW improves skin. Changing the route and adding two ingredients creates a different intervention. The question is whether the finished combination was tested for the outcome being claimed. The cited tendon experiment did not include GHK-Cu. It therefore cannot answer whether adding copper peptide improves, worsens, or leaves recovery unchanged.[3] A longer ingredient list does not establish a larger effect. Keep a claim about skin appearance separate from a claim about tendon strength, pain, or return to sport.
Safety & interactions
FDA identifies limited human safety data and potential immune-reaction concerns for injectable GHK-Cu.[4] Combining ingredients introduces a separate question about the mixture. The selected papers do not establish its compatibility, long-term safety, or a validated administration schedule.[2][3] Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms.
Forms & dosing
No validated regimen for the complete blend is established by the studies discussed here. A topical skin protocol is not an injectable-stack protocol.[2][3] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Human researchIndirect topical human trial.[2] This study tests a skin regimen rather than GLOW.[2] Main limitation: Route and intervention differ from the stack.[2] | ||
| Animal or cell researchIndirect animal combination research.[3] The experiment did not test the three-component combination.[3] Main limitation: A missing treatment group cannot establish an added effect.[3] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy
BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157
Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
Effects of BPC-157 and TB-500 on Achilles tendon healing
Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short- Bowel Rats
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157
Impact of pentadecapeptide BPC 157 on muscle healing
In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src‑Caveolin‑1‑endothelial nitric oxide synthase pathway
Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy
Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension
Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157
Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion
Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats
Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS
Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights
The anti-nociceptive effect of BPC-157 on the incisional pain model in rats
The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study
Ectopic Expression of Human Thymosin β4 Confers Resistance to Legionella pneumophila during Pulmonary and Systemic Infection in Mice
Expression and localisation of thymosin beta- 4 in the developing human early fetal heart
Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma
Hypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
Hypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4
Identifi cation of Thymosin β 4 as an effector of Hand1-mediated vascular development
Local Photorelease of Caged Thymosin β4 in Locomoting Keratocytes Causes Cell Turning
Modulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio: Possible implication in the regulation of actin dynamics
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
Recombinant Human Thymosin β4 Attenuates Endotoxemia-Induced ALI and EAE by Suppressing Inflammatory and Oxidative Responses
Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease
Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis
Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function
Serum thymosin β4 levels in patients with hepatitis B virusrelated liver failure
Significance of Thymosin β4 and Implication of PINCH-1-ILK-α-Parvin (PIP) Complex in Human Dilated Cardiomyopathy
Structural basis of actin sequestration by thymosin-β4: implications for WH2 proteins
Synthesis of thymosin β4 by peritoneal macrophages and adherent spleen cells
The Control of Actin Nucleotide Exchange by Thymosin β4 and Profilin. A Potential Regulatory Mechanism for Actin Polymerization in Cells
Thymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model
Thymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice
Thymosin β4 Regulates Focal Adhesion Formation in Human Melanoma Cells and Affects Their Migration and Invasion
Thymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models
Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell–derived cardiomyocytes in a porcine model of acute myocardial infarction
Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells
Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction
Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF- κB signaling axis in APP/PS1 mice
Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing
Thymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells
Thymosin-β4 Regulates Motility and Metastasis of Malignant Mouse Fibrosarcoma Cells
Thymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells
Thymosin β4: A ubiquitous peptide in rat and mouse tissues
Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids
Thymosin beta‑4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
Thymosin β4 Sequesters the Majority of G-actin in Resting Human Polymorphonuclear Leukocytes
A Torilis japonica Extract–GHK-Cu Complex Attenuates Th2 Cytokines and Promotes Keratinocyte Recovery: A Potential Antioxidant Strategy for Atopic Dermatitis
A gene expression signature of emphysemarelated lung destruction and its reversal by the tripeptide GHK
Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu
Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth
Enhanced biological properties of collagen/chitosan‑coated poly(ε‑caprolactone) scaffold by surface modification with GHK‑Cu peptide and 58S bioglass
Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms
Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway
Glycyl-L-histidyl-L-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway
Glycyl- l -histidyl- l -lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro
Human skin penetration of a copper tripeptide in vitro as a function of skin layer
Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy
Improved laccase production by Trametes versicolor using Copper-Glycyl-L-Histidyl-L-Lysine as a novel and high-efficient inducer
In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer
In Vivo Stimulation of Connective Tissue Accumulation by the Tripeptide-Copper Complex Glycyl-L-histidyl-L-lysine-Cu2+ in Rat Experimental Wounds
Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application
Mass spectral and theoretical investigations of the transient proton-bound dimers on the cleavage processes of the peptide GHK and its analogues
Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs
The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline
The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds
The copper(II)-binding tripeptide GHK, a valuable crystallization and phasing tag for macromolecular crystallography
The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6
The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharideinduced acute lung injury in mice
FAQs
What peptides are in the GLOW stack?
The commonly described combination is BPC-157, TB-500, and GHK-Cu. Check actual ingredients rather than relying on the nickname.[1] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.
Does GLOW regrow hair?
The selected GHK-Cu trial measured post-laser skin outcomes, not hair regrowth or the GLOW blend. It cannot support that conclusion.[2] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.
Is KLOW stronger than GLOW?
KLOW adds another ingredient, KPV. “Stronger” would require a defined outcome and a direct comparison; an extra ingredient does not provide that comparison.[1] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for GLOW stack.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
4 sources
- GLOW vs KLOW vs Wolverine Stack: Which One? — naming reference only (2026)Commercial description · Names and ingredients only
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006)Primary research · Human randomized trialReview status · PendingSave study
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (2026)Primary research · Animal experimentRead review · DraftSave study
- FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Accessed 2026-10-04)Regulatory assessmentSave study
